We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 15, 2006
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
The primary goal of this study is to determine how contingency management can best be combined with standard or high doses of methadone to increase simultaneous abstinence from heroin and cocaine.

Condition Intervention Phase
Opioid Dependence Cocaine Abuse Drug: Methadone Behavioral: Contingency Management Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Enrollment: 200
Study Start Date: June 1999
Study Completion Date: August 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Detailed Description:
A study of people pmaintained on Methadone using contingency management

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Opioid dependence; cocaine use

Exclusion Criteria:

  • Medical or psychiatric conditions that would contraindicate participation in a methadone maintenance study; inability to give informed consent; inability to attend clinic seven days a week
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00292123

Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Kenzie Preston, PhD NIFA Intramural Research Program
  More Information

Ghitza UE, Epstein DH, Preston KL. Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addict Behav. 2008 Apr;33(4):593-604. Epub 2007 Nov 17.
Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat. 2008 Jul;35(1):78-86. Epub 2007 Oct 10.
Ghitza UE, Epstein DH, Schmittner J, Vahabzadeh M, Lin JL, Preston KL. Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin. J Consult Clin Psychol. 2007 Oct;75(5):765-74.
Ghitza UE, Epstein DH, Preston KL. Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend. 2007 Dec 1;91(2-3):169-77. Epub 2007 Jul 10.
Heinz A, Epstein DH, Preston KL. Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs. 2007 Mar;39(1):41-9.
Heinz AJ, Epstein DH, Schroeder JR, Singleton EG, Heishman SJ, Preston KL. Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat. 2006 Dec;31(4):355-64. Epub 2006 Aug 1.
Ghitza UE, Epstein DH, Preston KL. Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav. 2007 May;32(5):938-49. Epub 2006 Aug 1.

Responsible Party: Kenzie L. Preston, Ph.D., Principal Investigator, National Institute on Drug Abuse
ClinicalTrials.gov Identifier: NCT00292123     History of Changes
Other Study ID Numbers: NIDAIRP 326
First Submitted: February 14, 2006
First Posted: February 15, 2006
Last Update Posted: January 12, 2017
Last Verified: December 2007

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents

To Top